Helicobacter pylori infection
Conditions
Interventions
Intervention Group:vonoprazan (20 mg once daily), colloidal bismuth pectin capsules (200 mg twice daily), amoxicillin capsules (1000 mg twice daily), and Tetracycline (500 mg three times daily)
Control Group:vonoprazan (20 mg twice daily), colloidal bismuth pectin capsules (200 mg twice daily), amoxicillin capsules (1000 mg twice daily), and Tetracycline (500 mg three times daily)
Sponsors
Taizhou Hospital of Zhejiang Province
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. 18 years old <= age <=70 years old 2. Positive Helicobacter pylori (Hp) test (as determined by ¹³ C-urea breath test, ¹4 C-urea breath test, and histopathology) 3. no previous history of H. pylori eradication therapy 4. Subjects who fully understood the content of the trial, volunteered to participate in the trial and were able to complete the trial process, and signed the informed consent
Exclusion criteria
Exclusion criteria: 1. Use of acid-suppressive drugs, such as proton pump inhibitors, potassium competitive acid blockers, histamine H2 receptor antagonists, etc., within 2 weeks before enrollment, or use of antibiotics 4 weeks before enrollment 2. Active peptic ulcer with bleeding, perforation, obstruction, cancer and other complications 3. Previous esophageal or gastric surgery 4. Patients with serious systemic diseases, major organ diseases such as heart, lung, brain diseases, liver and kidney dysfunction, malignant tumors or other diseases 5. Known to be allergic to vonoprazan, amoxicillin, tetracycline, bismuth, etc 6. Pregnant or lactating women 7. Other persons considered by the investigator to be ineligible for the trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| H. pylori eradication rates; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse Reaction Incidence; | — |
Countries
China
Contacts
Public ContactLingling Yan
Taizhou Hospital of Zhejiang Province
Outcome results
None listed